Answer
No. It reduces kallikrein–bradykinin activity involved in attacks but does not remove the underlying inherited condition.
Sources for this answer
- TAKHZYRO 150 mg solution for injection in pre-filled syringe — Current selected SmPCemc · Summary of Product Characteristics
- NHSNHS · NHS medicine guidance
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.